Sand Hill Global Advisors LLC Purchases 177,288 Shares of Doximity, Inc. $DOCS

Key Points

• Sand Hill Global Advisors LLC has significantly increased its stake in Doximity, purchasing an additional 177,288 shares, totaling 240,301 shares owned, which reflects a growth of 281.4%.
• Insider transactions show that Director Regina M. Benjamin sold 5,000 shares for $315,000, reducing her stake by 23.13%, while insiders collectively sold 36,000 shares worth over $2 million in the last quarter.
• Doximity has received positive analyst ratings, with upgrades and increased price targets from several research firms, suggesting a consensus rating of "Moderate Buy" among analysts.

Sand Hill Global Advisors LLC raised its position in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 281.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,301 shares of the company's stock after purchasing an additional 177,288 shares during the period. Sand Hill Global Advisors LLC owned approximately 0.13% of Doximity worth $13,945,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in DOCS. Envestnet Asset Management Inc. raised its position in Doximity by 19.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 162,905 shares of the company's stock valued at $8,697,000 after purchasing an additional 27,001 shares in the last quarter. Sterling Capital Management LLC raised its position in Doximity by 57.9% during the fourth quarter. Sterling Capital Management LLC now owns 6,929 shares of the company's stock valued at $370,000 after purchasing an additional 2,542 shares in the last quarter. Townsquare Capital LLC purchased a new stake in Doximity during the fourth quarter valued at about $220,000. Barclays PLC raised its position in Doximity by 191.1% during the fourth quarter. Barclays PLC now owns 155,447 shares of the company's stock valued at $8,299,000 after purchasing an additional 102,046 shares in the last quarter. Finally, Mariner LLC raised its position in Doximity by 27.5% during the fourth quarter. Mariner LLC now owns 31,309 shares of the company's stock valued at $1,672,000 after purchasing an additional 6,753 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company's stock.

Insider Activity at Doximity

In related news, Director Regina M. Benjamin sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the transaction, the director owned 16,618 shares in the company, valued at $997,080. The trade was a 37.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Timothy S. Cabral sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director owned 6,360 shares in the company, valued at approximately $381,600. This represents a 61.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,000 shares of company stock worth $2,140,940 in the last 90 days. Company insiders own 31.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DOCS. Raymond James Financial raised their price target on Doximity from $65.00 to $75.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. BTIG Research upgraded Doximity from a "neutral" rating to a "buy" rating and set a $80.00 price target on the stock in a research report on Monday, June 2nd. KeyCorp lifted their price objective on Doximity from $65.00 to $70.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. JPMorgan Chase & Co. dropped their target price on Doximity from $63.00 to $60.00 and set a "neutral" rating for the company in a report on Tuesday, May 27th. Finally, Wells Fargo & Company raised their price target on Doximity from $55.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Monday, August 4th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, Doximity presently has an average rating of "Moderate Buy" and a consensus target price of $66.21.

Doximity Price Performance

Doximity stock traded up $3.5630 during trading hours on Friday, reaching $67.6930. The company had a trading volume of 1,637,248 shares, compared to its average volume of 2,323,116. Doximity, Inc. has a 12-month low of $35.32 and a 12-month high of $85.21. The firm has a market cap of $12.68 billion, a price-to-earnings ratio of 67.69, a P/E/G ratio of 4.10 and a beta of 1.36. The company has a 50-day moving average price of $60.80 and a 200 day moving average price of $60.46.

Doximity (NASDAQ:DOCS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.05. Doximity had a return on equity of 21.75% and a net margin of 36.60%.During the same quarter in the prior year, the firm posted $0.28 EPS. The business's revenue for the quarter was up 15.2% compared to the same quarter last year. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, research analysts expect that Doximity, Inc. will post 0.99 earnings per share for the current year.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.